

Fast-tracking clinical research timelines

The countdown

Speed is critical at every stage. But R&D efficiency is elusive.



Pharma leaders who say **drug production takes longer** now than two years agoⁱ



Median delay in study duration among completed trialsⁱⁱ



Phase I assets that **fail to launch**ⁱⁱⁱ



ACCELERATE YOUR DEVELOPMENT >

The slowdowns

A few vital factors **consistently delay** drug development.



- ✘ **Competition for sites and patients**, with a 50% increase in studies^{iv}
- ✘ Patient recruitment as the **no. 1 industry challenge**^v
- ✘ **15% increase in the cost** to develop a new drug^{vi}
- ✘ Increasing clinical trial **complexity**^{vii}

The time saver

A trusted partner that demonstrably accelerates the clinical journey: enter **the PPD™ clinical research business** of Thermo Fisher Scientific.



faster site activation than industry average

better CRA retention rate than industry average



- ✔ Therapeutic expertise **built over nearly 40 years**
- ✔ **Go-to collaborator**
 - Collaboration with **all the top 50 pharmaceutical companies**
 - Work on **all the top 10 selling drugs and biologics**
- ✔ **Proven track record**
 - Built over **nearly 40 years**
 - **2,800+ studies** overseen in the last five years

The accelerator

Solutions built to **surpass milestones**.



- ✔ **Data-driven** patient participation
- ✔ Predictive and **dynamic analytics**
- ✔ **Complete services** across the drug development spectrum
- ✔ Breadth and depth of **FSP capabilities**

The finish line

Patients are waiting. **You shouldn't.**

Make every moment matter.



ACCELERATE YOUR RESEARCH TODAY >

ⁱ <https://www.ppd.com/pharmaceuticals-research-and-development/>

ⁱⁱ <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2800488#:~:text=The%20median%20delay%20among%20completed,of%20the%20planned%20study%20sample.>

ⁱⁱⁱ <https://www.mckinsey.com/industries/life-sciences/our-insights/accelerating-clinical-trials-to-improve-biopharma-r-and-d-productivity>

^{iv} <https://classic.clinicaltrials.gov/ct2/resources/trends>

^v <https://www.ppd.com/pharmaceuticals-research-and-development/>

^{vi} <https://www2.deloitte.com/us/en/pages/life-sciences-and-health-care/articles/measuring-return-from-pharmaceutical-innovation.html>

^{vii} <https://www.centerwatch.com/articles/25921-no-end-in-sight-for-trial-complexity-csdd-report-reveals>